

CITATION REPORT

List of articles citing

Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy

DOI: 10.1016/j.ejim.2020.05.011

European Journal of Internal Medicine, 2020, 76, 36-42.

Source: <https://exaly.com/paper-pdf/84403563/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
148	COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics. 2020 , 12,		9
147	Actualizaci3n de la Declaraci3n de consenso en medicina critica para la atenci3n multidisciplinaria del paciente con sospecha o confirmaci3n diagn3stica de COVID-19. 2020 , 20, 1-112		2
146	Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis. 2020 , 7, 586221		30
145	The Association of Inflammatory Cytokines in the Pulmonary Pathophysiology of Respiratory Failure in Critically Ill Patients With Coronavirus Disease 2019. 2020 , 2, e0203		16
144	Pandemic treatments on trial: the bigger picture.. 2020 , 56,		2
143	Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial. <i>International Immunopharmacology</i> , 2020 , 89, 107102	5.8	19
142	Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study. 2020 , 114, 102523		38
141	Repurposing Existing Drugs for the Treatment of COVID-19. 2020 , 17, 1186-1194		15
140	IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections. 2020 , 7, 583897		79
139	The effect of tocilizumab on cytokine release syndrome in COVID-19 patients. 2020 , 72, 1529-1537		6
138	COVID-19 in Elderly Adults: Clinical Features, Molecular Mechanisms, and Proposed Strategies. 2020 , 11, 1481-1495		6
137	Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm?. 2020 , 8, 677		30
136	COVID-19: Pharmacology and kinetics of viral clearance. 2020 , 161, 105114		11
135	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1. 2020 , 72, 1791-1805		184
134	Tocilizumab therapy in individuals with COVID-19 infection and hyperinflammatory state. 2020 , 25, 1090-1094		7
133	Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. 2020 , 180, 114169		19
132	Tocilizumab for severe COVID-19: a systematic review and meta-analysis. 2020 , 56, 106103		104

131	Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment. 2020 , 2020, 7527953		87
130	Targeting IL-6 in COVID-19. Response to: Rational use of tocilizumab in COVID-19 by Jain and Sharma. 2020 ,		1
129	[Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia]. 2020 , 155, 548-556		27
128	Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. 2020 , 2, e603-e612		173
127	Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review. 2020 , 57, 236-243		23
126	SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment. <i>Frontiers in Immunology</i> , 2020 , 11, 570927	8.4	21
125	Redefining the Prognostic Value of High-Sensitivity Troponin in COVID-19 Patients: The Importance of Concomitant Coronary Artery Disease. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	20
124	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. <i>Frontiers in Immunology</i> , 2020 , 11, 562264	8.4	5
123	COVID-19 multidisciplinary high dependency unit: the Milan model. 2020 , 21, 260		14
122	Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant Recipients. 2020 , 7, 1-11		8
121	The role of Interleukin 6 inhibitors in therapy of severe COVID-19. 2020 , 131, 110698		46
120	Immunomodulators in COVID-19: Two Sides to Every Coin. 2020 , 202, 1460-1462		11
119	Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients. 2020 , 23, 1030-1039		8
118	A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs. <i>Frontiers in Pharmacology</i> , 2020 , 11, 584956	5.6	30
117	Can Natural Polyphenols Help in Reducing Cytokine Storm in COVID-19 Patients?. 2020 , 25,		15
116	SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. <i>Frontiers in Immunology</i> , 2020 , 11, 569760	8.4	12
115	May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)?. 2020 , 18, 489		4
114	Eosinophilia and abdominal pain after severe pneumonia due to COVID 19. 2020 , 39, 478-478		1

113	A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019. 2020 , 2, e0283		14
112	Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of gene polymorphisms in novel coronavirus pneumonia. <i>Medicina Clínica (English Edition)</i> , 2020 , 155, 548-556	0.3	8
111	Tocilizumab and liver injury in patients with COVID-19. 2020 , 13, 1756284820959183		13
110	Predicting Clinical Outcome with Phenotypic Clusters in COVID-19 Pneumonia: An Analysis of 12,066 Hospitalized Patients from the Spanish Registry SEMI-COVID-19. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	29
109	Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation. <i>European Journal of Internal Medicine</i> , 2020 , 76, 21-22	3.9	14
108	Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced PANICTattack. 2020 , 415, 116935		24
107	NK cells: A double edge sword against SARS-CoV-2. 2020 , 77, 100737		44
106	Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids. <i>Frontiers in Immunology</i> , 2020 , 11, 1445	8.4	20
105	Late onset infectious complications and safety of tocilizumab in the management of COVID-19. <i>Journal of Medical Virology</i> , 2021 , 93, 1459-1464	19.7	38
104	Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study. 2021 , 19, 93-100		21
103	Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. 2021 , 27, 52-66		69
102	COVID-19: What type of cytokine storm are we dealing with?. <i>Journal of Medical Virology</i> , 2021 , 93, 197-198	19.7	7
101	Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. 2021 , 181, 41-51		213
100	Predictors and outcomes of healthcare-associated infections in COVID-19 patients. 2021 , 104, 287-292		28
99	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. 2021 , 73, e13-e29		149
98	Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19. <i>European Journal of Internal Medicine</i> , 2021 , 83, 34-38	3.9	14
97	Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature. 2021 , 538, 151-155		2
96	A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients. 2021 , 34, e14662		15

95	Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19. 2021 , 138, 155393		1
94	Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. 2021 , 35, 1121-1133		35
93	The effect of drugs used in rheumatology for treating SARS-CoV2 infection. 2021 , 21, 219-228		3
92	A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients. 2021 , 12, 20406223211039699		3
91	Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain. 2021 , 14, 249-260		4
90	The Novel Coronavirus and Inflammation. 2021 , 1321, 127-138		3
89	Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm. 2021 , 11,		28
88	Endothelial Dysfunction as a Primary Consequence of SARS-CoV-2 Infection. 2021 , 1321, 33-43		6
87	Effects of tocilizumab versus hemoadsorption combined with tocilizumab in patients with SARS-CoV-2 pneumonia: Preliminary results. 2021 , 391398821989334		2
86	Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. 2021 , 76, 907-919		49
85	Differential Cytokine Signatures of SARS-CoV-2 and Influenza Infection Highlight Key Differences in Pathobiology.		1
84	Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. 2021 , 22, 275-296		56
83	The Rheumatology Drugs for COVID-19 Management: Which and When?. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	8
82	Safety of tocilizumab in COVID-19 pregnant women and their newborn: A retrospective study. 2021 , 46, 1062-1070		9
81	Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis. <i>Frontiers in Pharmacology</i> , 2021 , 12, 607408	5.6	10
80	An Overview of Current Knowledge of Deadly CoVs and Their Interface with Innate Immunity. 2021 , 13,		7
79	Interleukin-6 Antagonists: Lessons From Cytokine Release Syndrome to the Therapeutic Application in Severe COVID-19 Infection. 2021 , 8971900211000691		4
78	Heparin-induced thrombocytopenia and COVID-19. 2021 , 13, 8857		9

77	Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 520-531	9.5	164
76	Utility of hospitalization for elderly individuals affected by COVID-19. 2021 , 16, e0250730		4
75	Tocilizumab: From Rheumatic Diseases to COVID-19. 2021 , 27, 1597-1607		0
74	Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia. 2021 ,		0
73	Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis. 2021 , 11, 95-109		1
72	Differential Cytokine Signatures of SARS-CoV-2 and Influenza Infection Highlight Key Differences in Pathobiology. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	5
71	A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19.		11
70	The Immunopathobiology of SARS-CoV-2 Infection. 2021 , 45,		1
69	Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database. 2021 , 20, 1125-1136		7
68	Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. 2021 , 9,		9
67	Incidence of secondary blood stream infections in Covid 19 (SARS-nCoV II.) patients. 2021 , 8, 128-131		
66	The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2. 2021 , 121, 705-714		3
65	Adverse Cardiovascular Effects of Anti-COVID-19 Drugs. <i>Frontiers in Pharmacology</i> , 2021 , 12, 699949	5.6	7
64	Laboratory parameters predicting mortality of adult in-patients with COVID-19 associated cytokine release syndrome treated with high-dose tocilizumab. 2021 ,		2
63	Eosinophilia and abdominal pain after severe pneumonia due to COVID 19. 2021 , 39, 478-480		1
62	Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study. 2021 , 16, e0257376		2
61	Tocilizumab in COVID-19: The Cerrahpaş-PREDICT score. 2021 , 27, 1329-1335		6
60	How did COVID-19 affect medical and cardiology journals? A pandemic in literature. 2021 , 22, 840-847		2

59	Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis. 2021 , 41, 884-906		7
58	A High Frequency of <i>Candida auris</i> Blood Stream Infections in Coronavirus Disease 2019 Patients Admitted to Intensive Care Units, Northwestern India: A Case Control Study.		7
57	The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. 2021 , 18,		5
56	On the role of bacterial metalloproteases in COVID-19 associated cytokine storm. 2021 , 19, 7		1
55	The Effect of IL-6 Inhibitors on Mortality Among Hospitalized COVID-19 Patients: A Multicenter Study. 2021 , 223, 581-588		3
54	A systematic review and meta-analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for Covid-19.		14
53	IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. 2020 ,		16
52	Addition of Tocilizumab to the standard of care reduces mortality in severe COVID-19: A systematic review and meta-analysis.		6
51	The Efficacy of IL-6 Inhibitor Tocilizumab in Reducing Severe COVID-19 Mortality: A Systematic Review.		7
50	Beneficial and harmful outcomes of tocilizumab in severe COVID-19: a systematic review and meta-analysis.		3
49	Anakinra and Intravenous IgG versus Tocilizumab in the Treatment of COVID-19 Pneumonia.		2
48	Coronavirus disease-2019 (COVID-19): value of IL-6 inhibitors. <i>Pulmonologiya</i> , 2020 , 30, 629-644	0.8	4
47	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. <i>Infection and Drug Resistance</i> , 2020 , 13, 4673-4695	4.2	20
46	Fungal Infections in COVID-19-Positive Patients: A Lack of Optimal Treatment Options. <i>Current Topics in Medicinal Chemistry</i> , 2020 , 20, 1951-1957	3	12
45	Coronavirus disease 2019 in critically ill patients: can we re-program the immune system? A primer for Intensivists. <i>Minerva Anestesiologica</i> , 2020 , 86, 1214-1233	1.9	1
44	Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. <i>Frontiers in Pharmacology</i> , 2020 , 11, 598308	5.6	14
43	Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020 , 11, 615972	5.6	21
42	Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers. <i>Indian Journal of Critical Care Medicine</i> , 2020 , 24, 771-776	1.3	6

41	The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review. <i>PeerJ</i> , 2020 , 8, e10322	3.1	25
40	Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current Evidence. <i>Cureus</i> , 2020 , 12, e10869	1.2	17
39	Modulation of Covid-19 cytokine storm by tocilizumab. <i>Journal of Medical Virology</i> , 2021 ,	19.7	4
38	One year later: The case of tocilizumab in COVID-19. <i>European Journal of Internal Medicine</i> , 2021 ,	3.9	2
37	The COVID-19: Current understanding. <i>Veterinary World</i> , 2020 , 13, 1998-2005	1.7	
36	Efficacy of Tocilizumab in Covid 19: A metanalysis of case series studies.		
35	COVID-19: Intensivmedizinische Aspekte und Langzeitfolgen. <i>Aktuelle Kardiologie</i> , 2021 , 10, 46-52	0.1	
34	Immunomodulatory drug therapy for the disease caused by SARS-CoV-2 infection (COVID-19). <i>Al?manah Kliničkoj Mediciny</i> , 48, 51-67	0.2	0
33	Predicting clinical outcome with phenotypic clusters in COVID-19 pneumonia: an analysis of 12,066 hospitalized patients from the Spanish registry SEMI-COVID-19.		
32	Tocilizumab in severe COVID-19: A promise fulfilled. <i>European Journal of Internal Medicine</i> , 2021 ,	3.9	2
31	Efficacy and Safety of Immunomodulators in Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Infectious Diseases and Therapy</i> , 2021 , 11, 231	6.2	2
30	Retrospective Analysis of Clinical Laboratory Parameters, Therapeutics and Outcome in Patients Infected with SARS-CoV2. <i>Indian Journal of Clinical Biochemistry</i> , 2021 , 1-7	2.2	
29	Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regression. <i>Clinical Microbiology and Infection</i> , 2021 ,	9.5	9
28	Early Fall in C-Reactive Protein (CRP) Level Predicts Response to Tocilizumab in Rapidly Progressing COVID-19: Experience in a Single-Arm Pakistani Center.. <i>Cureus</i> , 2021 , 13, e20031	1.2	0
27	An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).. <i>International Immunopharmacology</i> , 2022 , 105, 108536	5.8	4
26	Prevalence of comorbidities and symptoms stratified by severity of illness amongst adult patients with COVID-19: a systematic review.. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2022 , 7, e5-e23	6.9	0
25	A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence.. <i>European Journal of Clinical Investigation</i> , 2022 , e13763	4.6	1
24	Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.. <i>Frontiers in Immunology</i> , 2022 , 13, 795385	5.4	3

23	Association of Tocilizumab and Invasive Aspergillosis in Critically Ill Patients with Severe COVID-19 Pneumonia and Acute Respiratory Distress Syndrome.. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022 , 8,	5.6	0
22	Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.. <i>Clinical Infectious Diseases</i> , 2022 ,	11.6	8
21	Efficacy of tocilizumab in severe COVID-19: a retrospective study. <i>Journal of Health Sciences and Medicine</i> , 2022 , 5, 592-599	0	0
20	Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials.. <i>European Journal of Internal Medicine</i> , 2022 ,	3.9	0
19	Comparison between Dexamethasone and Methylprednisolone Therapy in Patients with COVID-19 Pneumonia Admitted to Non-Intensive Medical Units.. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
18	Safety of Therapy with Tocilizumab and Other Interleukin Inhibitors. <i>Safety and Risk of Pharmacotherapy</i> , 2022 , 10, 34-47	1.2	
17	Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials.. <i>International Immunopharmacology</i> , 2022 , 109, 108786	5.8	0
16	Image_1.JPEG. 2020 ,		
15	Image_2.JPEG. 2020 ,		
14	Table_1.docx. 2020 ,		
13	datasheet1.docx. 2020 ,		
12	Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	2
11	Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.. <i>Medicina Clinica (English Edition)</i> , 2022 , 158, 301-307	0.3	
10	Interleukin 6 inhibition in severe COVID-19: Another piece of the puzzle.. <i>European Journal of Internal Medicine</i> , 2022 ,	3.9	
9	COVID-19 and the role of cytokines in this disease.. <i>Inflammopharmacology</i> , 2022 , 1	5.1	4
8	COVID-19 and C. auris: A Case-Control Study from a Tertiary Care Center in Lebanon. <i>Microorganisms</i> , 2022 , 10, 1011	4.9	0
7	Biologics in COVID-19 So Far: Systematic Review. <i>Pharmaceuticals</i> , 2022 , 15, 783	5.2	0
6	COVID-19, Mucormycosis and Cancer: The Triple Threat Hypothesis or Reality?. <i>Journal of Personalized Medicine</i> , 2022 , 12, 1119	3.6	0

- 5 Immune-related adverse events of biological immunotherapies used in COVID-19. 13, ○
- 4 Options of Treatment in SARS-CoV-2 Infections. **2021**, 70, 60-67 ○
- 3 Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection. **2022**, 23, 14462 ○
- 2 A new flexible regression model with application to recovery probability Covid-19 patients. 1-19 ○
- 1 Identifying potential pharmacological targets and molecular pathways of Meliae cortex for COVID-19 therapy. 14, ○